Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
November 12 Product: Intercept Pharmaceuticals Ocaliva Indication: Primary biliary cholangitis After initially delaying its decision last month, the FDA on Tuesday declined to give Intercept Pharmaceuticals Ocaliva (obeticholic acid) full approval for primary biliary cholangitis (PBC)
The 1.3% gap between pill and injection is unlikely to be clinically meaningful for most people
Under these conditions, lyophilized retatrutide maintains stability for 24+ months
SGLT-2 inhibitors have a well-documented association with UTIs and genital infections because they literally create a sugar-rich environment in the urinary tract
Over the course of a 48-week protocol with weekly injections, that dead volume waste adds up to 1-2.5mL of wasted solution
US$ 27.23
US$ 20.15
US$ 29.24
